Many Biotech Patents At Risk After Fed. Circ. Myriad Ruling
By striking down Myriad Genetics Inc. breast cancer test patents Wednesday, the Federal Circuit greatly expanded the reach of a U.S. Supreme Court decision on Myriad's patents on human genes and...To view the full article, register now.
Already a subscriber? Click here to view full article